Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 18, 2000Proceedings of the National Academy of SciencesOpen Access

Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAlan R. SchoenfeldEDEliot J. DavidowitzRBRobert D. Burk

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Schoenfeld et al. (2000) studied this question.

synapsesocial.com/papers/6a1cc4e6f1b3da30e489a7e2https://doi.org/10.1073/pnas.97.15.8507
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A second major native von Hippel–Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor1998 · 230 citations
  2. 2Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene1993 · 3,022 citations
  3. 3Elongin (SIII): A Multisubunit Regulator of Elongation by RNA Polymerase II1995 · 337 citations
  4. 4The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins1997 · 502 citations
  5. 5pVHL <sub>19</sub> is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation1998 · 262 citations